Literature DB >> 19716081

Trends in utilization and complications of catheter ablation for atrial fibrillation in Medicare beneficiaries.

Ethan R Ellis1, Steven D Culler, April W Simon, Matthew R Reynolds.   

Abstract

BACKGROUND: Utilization of radiofrequency catheter ablation (RFA) for treatment of atrial fibrillation (AF) is increasing. Data regarding the safety of RFA for AF outside of selected centers of excellence and in older patients are limited.
OBJECTIVE: The purpose of this study was to quantify utilization of RFA for treatment of AF and rates of adverse events over time in unselected U.S. Medicare patients.
METHODS: Using Medicare Provider Analysis and Review (MedPAR) files for fiscal years 2001-2006, we developed a coding algorithm to identify AF patients treated with RFA. The number of hospitals performing the procedure, the number of procedures performed, and the frequency of eight RFA complications were determined. The impact of patient characteristics on complication rates was assessed using multivariable logistic regression.
RESULTS: For fiscal years 2001 to 2006, the number of hospitals performing RFA for AF in Medicare patients increased from 100 to 162, and the annual total procedure volume increased from 315 to 1975 cases. The overall complication rate was 9.1%. Annual complication rates increased from 6.7% in 2001 to 10.1% in 2006 (P for trend = .01), mainly due to an increase in rates of vascular access complications. Increasing patient age was not associated with a higher complication rate. Hospital procedural volume was not associated with the overall risk of complications but was associated with the probability of in-hospital death.
CONCLUSION: For fiscal years 2001-2006, use of RFA for treatment of AF increased markedly in the Medicare population. Overall complication rates rose during this time, with perforation/tamponade and vascular access complications accounting for the majority of events.

Entities:  

Mesh:

Year:  2009        PMID: 19716081      PMCID: PMC2958775          DOI: 10.1016/j.hrthm.2009.06.009

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  19 in total

1.  The impact of body mass index on short- and long-term outcomes inpatients undergoing coronary revascularization. Insights from the bypass angioplasty revascularization investigation (BARI).

Authors:  Hitinder S Gurm; Patrick L Whitlow; Kevin E Kip
Journal:  J Am Coll Cardiol       Date:  2002-03-06       Impact factor: 24.094

2.  Validity of information on comorbidity derived rom ICD-9-CCM administrative data.

Authors:  Hude Quan; Gerry A Parsons; William A Ghali
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

3.  Circumferential pulmonary-vein ablation for chronic atrial fibrillation.

Authors:  Hakan Oral; Carlo Pappone; Aman Chugh; Eric Good; Frank Bogun; Frank Pelosi; Eric R Bates; Michael H Lehmann; Gabriele Vicedomini; Giuseppe Augello; Eustachio Agricola; Simone Sala; Vincenzo Santinelli; Fred Morady
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

4.  Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation.

Authors:  Riccardo Cappato; Hugh Calkins; Shih-Ann Chen; Wyn Davies; Yoshito Iesaka; Jonathan Kalman; You-Ho Kim; George Klein; Douglas Packer; Allan Skanes
Journal:  Circulation       Date:  2005-02-21       Impact factor: 29.690

5.  Electrophysiological findings during ablation of persistent atrial fibrillation with electroanatomic mapping and double Lasso catheter technique.

Authors:  Feifan Ouyang; Sabine Ernst; Julian Chun; Dietmar Bänsch; Yigang Li; Anselm Schaumann; Hercules Mavrakis; Xingpeng Liu; Florian T Deger; Boris Schmidt; Yumei Xue; Jiang Cao; Detlef Hennig; He Huang; Karl-Heinz Kuck; Matthias Antz
Journal:  Circulation       Date:  2005-11-07       Impact factor: 29.690

6.  Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study).

Authors:  Giuseppe Stabile; Emanuele Bertaglia; Gaetano Senatore; Antonio De Simone; Franco Zoppo; Giovanni Donnici; Pietro Turco; Pietro Pascotto; Massimo Fazzari; Dino Franco Vitale
Journal:  Eur Heart J       Date:  2005-10-07       Impact factor: 29.983

7.  Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial.

Authors:  Oussama M Wazni; Nassir F Marrouche; David O Martin; Atul Verma; Mandeep Bhargava; Walid Saliba; Dianna Bash; Robert Schweikert; Johannes Brachmann; Jens Gunther; Klaus Gutleben; Ennio Pisano; Dominico Potenza; Raffaele Fanelli; Antonio Raviele; Sakis Themistoclakis; Antonio Rossillo; Aldo Bonso; Andrea Natale
Journal:  JAMA       Date:  2005-06-01       Impact factor: 56.272

8.  Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.

Authors:  David J Cohen; A Michael Lincoff; Tara A Lavelle; Huei-Ling Chen; Ameet Bakhai; Ronna H Berezin; Daniel Jackman; Ian J Sarembock; Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2004-11-02       Impact factor: 24.094

9.  Brief communication: atrial-esophageal fistulas after radiofrequency ablation.

Authors:  Jennifer E Cummings; Robert A Schweikert; Walid I Saliba; J David Burkhardt; Fethi Kilikaslan; Eduardo Saad; Andrea Natale
Journal:  Ann Intern Med       Date:  2006-04-18       Impact factor: 25.391

10.  Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study.

Authors:  Pierre Jaïs; Bruno Cauchemez; Laurent Macle; Emile Daoud; Paul Khairy; Rajesh Subbiah; Mélèze Hocini; Fabrice Extramiana; Fréderic Sacher; Pierre Bordachar; George Klein; Rukshen Weerasooriya; Jacques Clémenty; Michel Haïssaguerre
Journal:  Circulation       Date:  2008-11-24       Impact factor: 29.690

View more
  35 in total

1.  Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.

Authors:  Ghanshyam Palamaner Subash Shantha; Prashant D Bhave; Saket Girotra; Denice Hodgson-Zingman; Alexander Mazur; Michael Giudici; Elizabeth Chrischilles; Mary S Vaughan Sarrazin
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2017-04

Review 2.  Transseptal Puncture: Devices, Techniques, and Considerations for Specific Interventions.

Authors:  Sharan Prakash Sharma; Rahul Nalamasu; Rakesh Gopinathannair; Chandrasekhar Vasamreddy; Dhanunjaya Lakkireddy
Journal:  Curr Cardiol Rep       Date:  2019-05-07       Impact factor: 2.931

3.  Race- and sex-related differences in care for patients newly diagnosed with atrial fibrillation.

Authors:  Prashant D Bhave; Xin Lu; Saket Girotra; Hooman Kamel; Mary S Vaughan Sarrazin
Journal:  Heart Rhythm       Date:  2015-03-23       Impact factor: 6.343

4.  Impact of Heart Failure Type on Thromboembolic and Bleeding Risk in Patients With Atrial Fibrillation on Oral Anticoagulation.

Authors:  Amgad Mentias; Alexandros Briasoulis; Ghanshyam Shantha; Paulino Alvarez; Mary Vaughan-Sarrazin
Journal:  Am J Cardiol       Date:  2019-02-28       Impact factor: 2.778

5.  Assessment of Sex Differences in the Initial Symptom Burden, Applied Treatment Strategy, and Quality of Life in Japanese Patients With Atrial Fibrillation.

Authors:  Nobuhiro Ikemura; Shun Kohsaka; Takehiro Kimura; Ikuko Ueda; Yoshinori Katsumata; Takahiko Nishiyama; Yoshiyasu Aizawa; Kojiro Tanimoto; Yukihiko Momiyama; Makoto Akaishi; Hideo Mitamura; Keiichi Fukuda; John A Spertus; Seiji Takatsuki
Journal:  JAMA Netw Open       Date:  2019-03-01

Review 6.  Highlights of the year in JACC 2012.

Authors:  Anthony N DeMaria; Jeroen J Bax; Gregory K Feld; Barry H Greenberg; Jennifer L Hall; Mark A Hlatky; Wilbur Y W Lew; João A C Lima; Ehtisham Mahmud; Alan S Maisel; Sanjiv M Narayan; Steven E Nissen; David J Sahn; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2013-01-22       Impact factor: 24.094

7.  Refining Stroke Prediction in Atrial Fibrillation Patients by Addition of African-American Ethnicity to CHA2DS2-VASc Score.

Authors:  Rajesh Kabra; Saket Girotra; Mary Vaughan Sarrazin
Journal:  J Am Coll Cardiol       Date:  2016-08-02       Impact factor: 24.094

8.  Administrative billing codes accurately identified occurrence of electrical cardioversion and ablation/maze procedures in a prospective cohort study of atrial fibrillation patients.

Authors:  Alexa N Ehlert; Susan R Heckbert; Kerri L Wiggins; Evan L Thacker
Journal:  Clin Cardiol       Date:  2017-12-06       Impact factor: 2.882

Review 9.  Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants?

Authors:  Jeffrey B Washam; Jonathan P Piccini
Journal:  J Thromb Thrombolysis       Date:  2016-02       Impact factor: 2.300

10.  Venous hemostasis postcatheter ablation of atrial fibrillation while under therapeutic levels of oral and intravenous anticoagulation.

Authors:  Ziad F Issa; Bashar S Amr
Journal:  J Interv Card Electrophysiol       Date:  2015-07-30       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.